GNFT - Theratechnologies NASH Data And Other News: The Good Bad And Ugly Of Biopharma
Theratechnologies announces positive report for tesamorelin in NASH
Theratechnologies Inc. (THTX) announced positive data corroborating the impact of tesamorelin in treating HIV-associated nonalcoholic steatohepatitis. The data has been gleaned from a sub-analysis of the Phase 2 study. The trial aimed to assess the impact of tesamorelin on the transcriptome of the liver biopsies in people living with HIV-associated nonalcoholic fatty liver disease.
The sub-analysis involved assessing paired liver biopsy specimens obtained from Phase 2 participants. The evaluation was done using Gene Set Enrichment Analysis and studied the impact of the drug candidate on